Continued Access to RXDX-105

Plain-language summary

This study aims to provide continued access to the drug RXDX-105 for patients who had previously been treated with it in a Phase 1/1b clinical trial. Only the 3 patients enrolled in the previous protocol were able to take part; no other patients were included. The study was carried out in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Memorial Sloan Kettering Cancer Center

Intervention

RXDX-105

Start date

12/14/2018

Estimated completion

9/30/2020

Countries

United States

Related genes

Locations

• New York, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):

Exclusion Criteria:

* Any patients other than those described above are excluded.